Innova Captab Limited Asset Resilience Ratio
Innova Captab Limited asset resilience ratio. Innova Captab Limited (INNOVACAP) has an Asset Resilience Ratio of 2.25% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Innova Captab Limited total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Innova Captab Limited (2019–2026)
Asset resilience ratio of Innova Captab Limited from 2019 to 2026. This chart shows how Innova Captab Limited's Asset Resilience Ratio has changed over time. See INNOVACAP free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Innova Captab Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Innova Captab Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs412.85 Million | 2.25% |
| Total Liquid Assets | Rs412.85 Million | 2.25% |
Asset Resilience Insights
- Limited Liquidity: Innova Captab Limited maintains only 2.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innova Captab Limited Industry Peers by Asset Resilience Ratio
Compare Innova Captab Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636 |
Drug Manufacturers - Specialty & Generic | 4.68% |
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR |
Drug Manufacturers - Specialty & Generic | 6.76% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479 |
Drug Manufacturers - Specialty & Generic | 0.03% |
|
Anhui Sunhere Pharmaceutical Excipients Co Ltd
SHE:300452 |
Drug Manufacturers - Specialty & Generic | 31.78% |
|
Hainan Huluwa Pharmaceutical Group Co Ltd
SHG:605199 |
Drug Manufacturers - Specialty & Generic | 0.95% |
|
Celon Pharma SA
WAR:CLN |
Drug Manufacturers - Specialty & Generic | 0.11% |
Innova Captab Limited Asset Resilience Ratio by Year (2019–2026)
Innova Captab Limited asset resilience ratio by year from 2019 to 2026. The table below shows the annual Asset Resilience Ratio data for Innova Captab Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 2.25% | Rs412.85 Million ≈ $4.46 Million |
Rs18.37 Billion ≈ $198.71 Million |
-0.90pp |
| 2025-03-31 | 3.15% | Rs497.62 Million ≈ $5.38 Million |
Rs15.80 Billion ≈ $170.92 Million |
-2.33pp |
| 2024-03-31 | 5.48% | Rs723.64 Million ≈ $7.83 Million |
Rs13.21 Billion ≈ $142.85 Million |
+5.13pp |
| 2023-03-31 | 0.34% | Rs35.00 Million ≈ $378.51K |
Rs10.19 Billion ≈ $110.17 Million |
+0.22pp |
| 2022-03-31 | 0.13% | Rs7.23 Million ≈ $78.19K |
Rs5.75 Billion ≈ $62.24 Million |
-1.80pp |
| 2021-03-31 | 1.92% | Rs70.99 Million ≈ $767.73K |
Rs3.70 Billion ≈ $39.97 Million |
+0.62pp |
| 2020-03-31 | 1.30% | Rs49.45 Million ≈ $534.78K |
Rs3.80 Billion ≈ $41.08 Million |
+0.39pp |
| 2019-03-31 | 0.92% | Rs30.12 Million ≈ $325.74K |
Rs3.29 Billion ≈ $35.53 Million |
-- |
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cepha… Read more